drugset / Trial / NCT04459065
Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery
Phase 1/2
Recruiting
36 enrolled
University of Saskatchewan
Western Economic Diversification Canada · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery.
Timeline
- Start
- 2020-09-01
- Primary completion
- 2026-09
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IRDye800CW-nimotuzumab | Diagnostic / imaging agent | 50 mg | Intravenous |
| Subject | IRDye800CW-nimotuzumab | Diagnostic / imaging agent | 100 mg | Intravenous |